The evolving landscape of hybrid viral vector architectures: a persisting niche
Summary
The development of hybrid viral vectors was historically driven by the need to overcome inherent limitations of individual viral platforms, including restricted payload capacity, narrow tropism, and limited control over genomic persistence. By integrating functional modules from diverse viral and non-viral systems, these chimeric constructs exploit complementary mechanisms to expand therapeutic potential.
Keywords
The development of hybrid viral vectors was historically driven by the need to overcome inherent limitations of individual viral platforms, including restricted payload capacity, narrow tropism, and limited control over genomic persistence. By integrating functional modules from diverse viral and non-viral systems, these chimeric constructs exploit complementary mechanisms to expand therapeutic potential. This review examines the architectural principles underlying hybrid vector design, framing their evolution as a logical extension of viral engineering strategies - such as pseudotyping and genetic chimerization - rather than as a retrospective response to the rise of non-viral delivery platforms. We highlight key structural configurations, including adenoviral, lentiviral, herpes simplex virus (HSV) amplicon, baculoviral, and bacteriophage-derived chimeras, as well as their integration with transposon systems (e.g., Sleeping Beauty) to enable enhanced persistence and increased cargo capacity. In parallel, we analyze the biological and technological trade-offs associated with increased structural complexity, including manufacturing constraints, cumulative immunogenicity, and regulatory challenges. Collectively, hybrid vector systems represent a modular and evolving design paradigm that complements advances in monoplatform vectors and remains a valuable approach for addressing complex therapeutic challenges, for example those requiring expanded capacity, multifunctionality, or combinatorial control of gene delivery outcomes.
Abstract from PubMed Central (PMID 42964595, PMC13720247). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Molecular pharmaceuticsCombined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
The Journal of clinical investigationA single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
